Your browser doesn't support javascript.
loading
Functional and antigenic landscape of the Nipah virus receptor binding protein.
Larsen, Brendan B; McMahon, Teagan; Brown, Jack T; Wang, Zhaoqian; Radford, Caelan E; Crowe, James E; Veesler, David; Bloom, Jesse D.
Afiliación
  • Larsen BB; Basic Sciences Division and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA 98109, USA.
  • McMahon T; Basic Sciences Division and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA 98109, USA.
  • Brown JT; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Wang Z; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Radford CE; Basic Sciences Division and Computational Biology Program, Fred Hutch Cancer Center, Seattle, WA 98109, USA.
  • Crowe JE; Department of Pathology Microbiology and Immunology, The Vanderbilt Vaccine Center, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Bloom JD; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
bioRxiv ; 2024 Apr 19.
Article en En | MEDLINE | ID: mdl-38659959
ABSTRACT
Nipah virus recurrently spills over to humans, causing fatal infections. The viral receptor-binding protein (RBP or G) attaches to host receptors and is a major target of neutralizing antibodies. Here we use deep mutational scanning to measure how all amino-acid mutations to the RBP affect cell entry, receptor binding, and escape from neutralizing antibodies. We identify functionally constrained regions of the RBP, including sites involved in oligomerization, along with mutations that differentially modulate RBP binding to its two ephrin receptors. We map escape mutations for six anti-RBP antibodies, and find that few antigenic mutations are present in natural Nipah strains. Our findings offer insights into the potential for functional and antigenic evolution of the RBP that can inform the development of antibody therapies and vaccines.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos